Methylene Blue

This is a completely normal and expected effect of methylene blue. The drug and its metabolites are excreted through the kidneys, and the blue-green pigment passes into the urine, giving it a distinctive color. This is harmless and typically resolves within 1–2 days of stopping the medication. Your stool may also appear blue-green for the same reason. If you notice red or brown discoloration of urine, contact your healthcare provider as this could indicate hemolysis (red blood cell breakdown).

This is a critically important question. Methylene blue is a monoamine oxidase inhibitor (MAOI), and combining it with common antidepressants including SSRIs (such as sertraline, fluoxetine, escitalopram), SNRIs (such as venlafaxine or duloxetine), or tricyclic antidepressants can cause a dangerous, potentially life-threatening condition called serotonin syndrome. If you are on any antidepressant and need methylene blue for an elective procedure, your doctor will typically need to plan a washout period before administration. In emergency situations (life-threatening methemoglobinemia), the benefit may still outweigh the risk, but close monitoring is essential. Always inform your doctor and pharmacist about all medications you are taking.

Surgeons use methylene blue as a visual dye to help identify structures that are otherwise difficult to see. Common surgical uses include mapping sentinel lymph nodes in breast cancer and melanoma surgery, identifying parathyroid glands during thyroid or parathyroid operations, delineating fistula tracts to guide complete removal, and marking tissue boundaries during procedures. The blue color provides a clear visual contrast against normal tissue. The doses used for surgical visualization are typically low and are chosen to minimize systemic effects.

Methylene blue works rapidly when given intravenously. In most patients, methemoglobin levels begin to fall within 30–60 minutes of IV administration, and significant clinical improvement in oxygen saturation and symptoms is typically seen within 1 hour. However, pulse oximetry readings are unreliable after methylene blue is given because the drug absorbs light at the same wavelength used by pulse oximeters — your care team will use a blood test called co-oximetry to accurately measure your methemoglobin levels. If levels do not respond, G6PD deficiency may be present, or the dose may need to be repeated.

Methylene blue should be used during pregnancy only when absolutely necessary and when the potential benefit outweighs the risk to the fetus. Historical use of methylene blue injected directly into the amniotic fluid (a procedure now abandoned) was associated with serious fetal harm including intestinal blockage and anemia. Systemic IV use for treatment of severe methemoglobinemia, where the mother's life is at risk, is generally considered justified despite fetal risk. Discuss the risks and benefits thoroughly with your obstetrician and specialist before any use during pregnancy.

Serotonin syndrome is a potentially life-threatening drug reaction caused by too much serotonin activity in the nervous system. Symptoms range from mild (shivering, diarrhea) to severe (muscle rigidity, fever, seizures, irregular heartbeat, and loss of consciousness). Methylene blue causes serotonin syndrome risk because it inhibits MAO-A, the enzyme that normally breaks down serotonin. When combined with drugs that also increase serotonin — such as antidepressants, tramadol, or triptans — serotonin accumulates to dangerous levels. The FDA issued a safety warning about this combination in 2011. Early recognition and treatment with cyproheptadine, benzodiazepines, and cooling measures are key to survival.

No — methylene blue is generally contraindicated in patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency. G6PD is an enzyme required to generate NADPH in red blood cells. NADPH is the fuel that methylene blue uses to reduce methemoglobin back to normal hemoglobin. In G6PD-deficient patients, NADPH cannot be made in sufficient quantities, so methylene blue simply cannot do its job — and worse, it may cause severe hemolytic anemia by acting as an oxidant that destroys red blood cells. For these patients, high-dose ascorbic acid (Vitamin C) or exchange transfusion are used as alternatives.

For treatment of ifosfamide-induced encephalopathy, the typical dose is 50 mg orally or intravenously every 4–6 hours until the encephalopathy resolves, which usually occurs within 24–48 hours. For prophylaxis in patients at high risk of encephalopathy during ifosfamide chemotherapy, 50 mg orally three times daily on the day(s) of ifosfamide infusion and continuing for 24 hours afterward is commonly used. The mechanism involves methylene blue's ability to act as an alternative electron acceptor, bypassing the defective mitochondrial electron transport caused by ifosfamide's toxic metabolite chloroacetaldehyde.